Nepal Halts Sales of Indian Antibiotic Biotax 1gm Amid Serious Health Risks
Nepal halts sales of Indian antibiotic due to serious health risks
The Department of Drug Administration in Nepal has recently made a significant move by suspending the sales and distribution of the Biotax 1gm antibiotic injection, manufactured by Zydus Healthcare Ltd, an Indian pharmaceutical company. The decision came after batch F300460 of the Biotax 1gm injection was found to be non-compliant with production specifications, potentially putting patients at serious health risks.
This suspension is crucial but does not disrupt patient treatment, as there are alternative injections in the market with the same composition available. The Biotax 1gm injection is commonly used to treat various bacterial infections affecting different parts of the body, such as the brain, lungs, ear, urinary tract, skin, soft tissues, bones, joints, blood, and heart.
The laboratory testing of the specific batch that led to the suspension revealed that it did not meet the required production specifications, leading to immediate orders to halt sales, import, and distribution by the manufacturing company, importers, and distributors.
Pramod KC, a spokesperson, emphasized that this precautionary measure is to prevent serious health risks to patients and ensure public safety. The investigation is ongoing, and further actions will be taken based on the results to protect public health and guarantee compliance with production specifications, aiming to prevent health risks associated with unsafe drugs.
This incident underscores the significance of strict regulations in the pharmaceutical industry to safeguard public health and safety. The Department of Drug Administration in Nepal is committed to ensuring that the medications available in the market meet the necessary standards for efficacy and safety.
Read also :Reduce Stress and Lead a Healthier Life on International Panic Day 2024 with These 6 Tips
